Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares conducted on November 3, 2025, and filed on November 4, 2025. The Company, a foreign private issuer, executed a share repurchase through BNP Paribas SA as part of an existing buyback programme established under a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics and Transaction Details
The filing details a specific share repurchase transaction rather than comprehensive financial results. Key metrics for the transaction are as follows:
- Shares Purchased: 170,500 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,758.50p; highest price paid was 1,782.00p.
- Average Price: Volume-weighted average price paid was 1,769.85p.
- Trading Venues: Purchases were executed across BATE, CHIX, and XLON.
- Treasury Holdings: Following this purchase, the Company holds 254,938,844 ordinary shares in treasury.
- Shares in Issue: 4,060,484,755 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 6.28% of total voting rights.
Material Changes and Programme Progress
Since the commencement of the current buyback phase on September 30, 2025, the Company has purchased an aggregate of 7,474,000 ordinary shares. The transaction reported herein is a continuation of this programme. The filing does not provide comparative financial data (revenue, profit, cash flow) for the period, as it is a disclosure of a capital transaction.
Guidance, Outlook, and Risks
The filing includes a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced in the Company's Annual Report on Form 20-F for 2024 and its Q3 Results for 2025. No new guidance or management commentary regarding operational outlook is provided in this specific document.
Investor Verification Checklist
- Verify the total cumulative buyback volume since September 30, 2025 (stated as 7,474,000 shares).
- Confirm the updated treasury share count of 254,938,844 and the resulting 6.28% voting rights attribution.
- Review the non-discretionary agreement terms announced on September 30, 2025, to understand the remaining capacity of the buyback programme.
- Check the Company's Form 20-F and Q3 2025 results for broader financial context and risk factors referenced in the cautionary statement.